RxDoctor Payments Data

Arthur Moswin, MD

Internal Medicine · Chicago, ILNPI 1023120094

Payments from drug & device makers

$561in general payments, 2019–2025

Across 40 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$260
  • Johnson & Johnson$97
  • AbbVie$48
  • Viiv Healthcare Company$47
  • Merck$40
  • Takeda Pharmaceuticals U.S.A., Inc.$29
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$561 in reported general payments places this provider in the 70th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$15,138
Medicare patients
27
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala258$1,028,008
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf85$394,834
GenvoyaElviteg/Cob/Emtri/Tenof Alafen71$301,826
DescovyEmtricitabine/Tenofov Alafenam56$132,141
TivicayDolutegravir Sodium53$119,128
DovatoDolutegravir Sodium/Lamivudine34$95,618
PrezcobixDarunavir/Cobicistat36$94,152
TriumeqAbacavir/Dolutegravir/Lamivudi23$87,530
JulucaDolutegravir/Rilpivirine22$73,803
JardianceEmpagliflozin43$55,414
RybelsusSemaglutide13$29,640
OzempicSemaglutide26$27,352
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df12$20,658
EvotazAtazanavir Sulfate/Cobicistat12$19,382
Darunavir12$18,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$260$1,461,974385 claims
Viiv Healthcare CompanyTivicay, Dovato, Triumeq, Juluca$47$376,079132 claims
Johnson & JohnsonPrezcobix$97$94,15236 claims
AbbVieLinzess$48$7,44412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →